StockData
Metagenomi Therapeutics, Inc. logo

Metagenomi Therapeutics, Inc. (MGX) stock

MGXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$0.63+0.00 (+0.13%)

Close on Nov 18, 2026Market cap $23.87MP/E –Yield –

Metagenomi Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Metagenomi Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $88.60M, down 8.7% year over year. For fiscal 2025 it was $94.43M, down 13.5% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$94.43M-13.5%
FY2024Dec 31, 2024$109.18M+15.7%
FY2023Dec 31, 2023$94.40M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$22.51M+0.0%
Q1 FY2026Mar 31, 2026$19.30M-23.2%
Q4 FY2025Dec 31, 2025$21.50M-7.2%
Q3 FY2025Sep 30, 2025$25.28M-3.7%
Q2 FY2025Jun 30, 2025$22.51M-20.5%
Q1 FY2025Mar 31, 2025$25.14M-20.0%
Q4 FY2024Dec 31, 2024$23.16M-6.4%
Q3 FY2024Sep 30, 2024$26.26M-2.2%
Q2 FY2024Jun 30, 2024$28.32M+24.9%
Q1 FY2024Mar 31, 2024$31.44M+56.2%
Q4 FY2023Dec 31, 2023$24.76M–
Q3 FY2023Sep 30, 2023$26.84M–
Q2 FY2023Jun 30, 2023$22.68M–
Q1 FY2023Mar 31, 2023$20.13M–

More Metagenomi Therapeutics figures

See a number that looks wrong?